Vimarsana
Biggest News Aggregation in the World

Cc 92480 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cc 92480. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cc 92480 Today - Breaking & Trending Today

Oral CELMoD Mezigdomide May Address Logistical Challenges Linked With R/R Myeloma Management - Vimarsana News

Oral CELMoD Mezigdomide May Address Logistical Challenges Linked With R/R Myeloma Management

Published: December 15, 2023

Paul G. Richardson, MD, shares clinical findings and several case studies showcasing the encouraging activity and safety of mezigdomide in patients with relapsed/refractory multiple myeloma.

Source: onclive.com
Related Topics:
Dana Farber Cancer InstituteUnited StatesOmar NadimPaulg RichardsonNizar BahlisClinical ResearchUniversity Of CalgaryMedicine At Harvard Medical SchoolJerome Lipper Multiple Myeloma CenterCharbonneau Cancer Research InstituteHarvard Medical SchoolCancer CareNew England JournalNorth AmericaActivity And Safety Of Mezigdomide In Patients With Relapsed Refractory Multiple MyelomaNovel Celmod Cc 92480Phase 1 2 Trial Nct03374085
Mezigdomide Plus Dexamethasone Elicits Responses With Acceptable Safety in R/R Myeloma - Vimarsana News

Mezigdomide Plus Dexamethasone Elicits Responses With Acceptable Safety in R/R Myeloma

Published: August 31, 2023

Treatment with combination of mezigdomide and dexamethasone produced responses with a safety profile that consisted primarily of myelotoxic adverse effects in heavily pretreated patients with relapsed/refractory multiple myeloma.

Source: onclive.com
Related Topics:
United StatesPaulg RichardsonInternational Staging SystemInternational Myeloma Working GroupNew England JournalJerome Lipper Multiple Myeloma CenterDana Farber Cancer CenterHarvard Medical SchoolMultiple MyelomaCc 92480Relapsed Refractory Multiple MyelomaNew England Journal Of Medicine